RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, gemtuzumab–ozogamicin seems to promote cell cycle progression in CML CD34+ cells and demonstrated activation of the RUNX1 pathway in an RNAseq experiment.